GNAQ and melanoma: As expected, the RAS pathway was mutated in the majority of melanomas (89%) and the MAPK pathway (GNA11 and GNAQ) in 4% of melanomas, displaying a mutually exclusive pattern with mutations in the RAS pathway (P = 0.001).